Clinuvel Pharmaceuticals Ltd Asset Resilience Ratio
Clinuvel Pharmaceuticals Ltd asset resilience ratio. Clinuvel Pharmaceuticals Ltd (CUV) has an Asset Resilience Ratio of 86.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Clinuvel Pharmaceuticals Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Clinuvel Pharmaceuticals Ltd (2006–2025)
Asset resilience ratio of Clinuvel Pharmaceuticals Ltd from 2006 to 2025. This chart shows how Clinuvel Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read Clinuvel Pharmaceuticals Ltd (CUV) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Clinuvel Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Clinuvel Pharmaceuticals Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$36.14 Million | 13.4% |
| Short-term Investments | AU$196.86 Million | 72.99% |
| Total Liquid Assets | AU$233.00 Million | 86.39% |
Asset Resilience Insights
- Very High Liquidity: Clinuvel Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 86.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Clinuvel Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Clinuvel Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Clinuvel Pharmaceuticals Ltd Asset Resilience Ratio by Year (2006–2025)
Clinuvel Pharmaceuticals Ltd asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Clinuvel Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 72.16% | AU$196.09 Million ≈ $138.74 Million |
AU$271.75 Million ≈ $192.28 Million |
+7.83pp |
| 2024-06-30 | 64.32% | AU$148.67 Million ≈ $105.19 Million |
AU$231.12 Million ≈ $163.53 Million |
-4.02pp |
| 2023-06-30 | 68.34% | AU$132.95 Million ≈ $94.07 Million |
AU$194.52 Million ≈ $137.64 Million |
+3.36pp |
| 2022-06-30 | 64.98% | AU$94.10 Million ≈ $66.58 Million |
AU$144.81 Million ≈ $102.47 Million |
+23.02pp |
| 2021-06-30 | 41.96% | AU$45.55 Million ≈ $32.23 Million |
AU$108.57 Million ≈ $76.82 Million |
-8.44pp |
| 2020-06-30 | 50.40% | AU$41.09 Million ≈ $29.08 Million |
AU$81.54 Million ≈ $57.70 Million |
+4.64pp |
| 2019-06-30 | 45.75% | AU$28.52 Million ≈ $20.18 Million |
AU$62.35 Million ≈ $44.11 Million |
+0.14pp |
| 2018-06-30 | 45.61% | AU$19.57 Million ≈ $13.85 Million |
AU$42.90 Million ≈ $30.36 Million |
+12.26pp |
| 2017-06-30 | 33.35% | AU$9.54 Million ≈ $6.75 Million |
AU$28.61 Million ≈ $20.24 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$20.14 Million ≈ $14.25 Million |
-- |
| 2012-06-30 | 2.84% | AU$453.60K ≈ $320.95K |
AU$16.00 Million ≈ $11.32 Million |
-23.55pp |
| 2011-06-30 | 26.39% | AU$5.32 Million ≈ $3.76 Million |
AU$20.17 Million ≈ $14.27 Million |
+0.67pp |
| 2010-06-30 | 25.72% | AU$7.59 Million ≈ $5.37 Million |
AU$29.51 Million ≈ $20.88 Million |
-12.84pp |
| 2009-06-30 | 38.55% | AU$16.04 Million ≈ $11.35 Million |
AU$41.61 Million ≈ $29.44 Million |
-7.01pp |
| 2008-06-30 | 45.57% | AU$25.05 Million ≈ $17.72 Million |
AU$54.97 Million ≈ $38.90 Million |
+3.53pp |
| 2007-06-30 | 42.04% | AU$28.51 Million ≈ $20.17 Million |
AU$67.82 Million ≈ $47.99 Million |
+30.18pp |
| 2006-06-30 | 11.86% | AU$2.02 Million ≈ $1.43 Million |
AU$17.07 Million ≈ $12.08 Million |
-- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more